JP2010520917A - 肥満治療用三環式イソキノリン誘導体 - Google Patents

肥満治療用三環式イソキノリン誘導体 Download PDF

Info

Publication number
JP2010520917A
JP2010520917A JP2009553146A JP2009553146A JP2010520917A JP 2010520917 A JP2010520917 A JP 2010520917A JP 2009553146 A JP2009553146 A JP 2009553146A JP 2009553146 A JP2009553146 A JP 2009553146A JP 2010520917 A JP2010520917 A JP 2010520917A
Authority
JP
Japan
Prior art keywords
azepino
tetrahydro
indole
alkyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009553146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520917A5 (cg-RX-API-DMAC7.html
Inventor
ヨハン・アングブラント
ペーター・ブラント
ルネ・リンゴム
ベンクト・リンドクヴィスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of JP2010520917A publication Critical patent/JP2010520917A/ja
Publication of JP2010520917A5 publication Critical patent/JP2010520917A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2009553146A 2007-03-13 2008-03-13 肥満治療用三環式イソキノリン誘導体 Withdrawn JP2010520917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0700611 2007-03-13
US202907P 2007-11-05 2007-11-05
PCT/EP2008/053002 WO2008110598A1 (en) 2007-03-13 2008-03-13 Tricyclic isoquinoline derivatives for treatment of obesity

Publications (2)

Publication Number Publication Date
JP2010520917A true JP2010520917A (ja) 2010-06-17
JP2010520917A5 JP2010520917A5 (cg-RX-API-DMAC7.html) 2011-05-06

Family

ID=39462457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009553146A Withdrawn JP2010520917A (ja) 2007-03-13 2008-03-13 肥満治療用三環式イソキノリン誘導体

Country Status (10)

Country Link
US (1) US8138333B2 (cg-RX-API-DMAC7.html)
EP (1) EP2134714A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010520917A (cg-RX-API-DMAC7.html)
CN (1) CN101631787A (cg-RX-API-DMAC7.html)
AU (1) AU2008225753A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0808791A2 (cg-RX-API-DMAC7.html)
CA (1) CA2679346A1 (cg-RX-API-DMAC7.html)
EA (1) EA016592B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ579360A (cg-RX-API-DMAC7.html)
WO (1) WO2008110598A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133325A1 (ja) * 2012-03-06 2013-09-12 武田薬品工業株式会社 三環性化合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101653707B1 (ko) * 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012106448A1 (en) * 2011-02-02 2012-08-09 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
US10675283B2 (en) 2017-03-24 2020-06-09 University Of South Florida Compositions and methods for white to beige adipogenesis
CN109180687A (zh) * 2018-08-31 2019-01-11 山东轩德医药科技有限公司 一种瑞卡帕步中间体的制备方法
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法
CN115925658B (zh) * 2022-11-21 2024-02-27 常州佳德医药科技有限公司 一种2-氨基乙基呋喃的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795451A (fr) * 1972-02-23 1973-08-16 Pfizer Agents hypoglycemiants aza indoliques tricycliques
US3950343A (en) * 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
CA2194984C (en) 1994-07-26 2002-07-02 John Eugene Macor 4-indole derivatives as serotonin agonists and antagonists
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
AU767009B2 (en) 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
KR100823908B1 (ko) 2000-10-20 2008-04-21 바이오비트럼 에이비(피유비엘) 2-, 3-, 4-, 또는 5-치환-n1-(벤젠술포닐)인돌 및 이의치료 용도
JP4390698B2 (ja) * 2002-06-05 2009-12-24 エフ.ホフマン−ラ ロシュ アーゲー Cns障害の処置のための5−ht6レセプターモジュレーターとしての1−スルホニル−4−アミノアルコキシインドール誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133325A1 (ja) * 2012-03-06 2013-09-12 武田薬品工業株式会社 三環性化合物
JPWO2013133325A1 (ja) * 2012-03-06 2015-07-30 武田薬品工業株式会社 三環性化合物
US9556200B2 (en) 2012-03-06 2017-01-31 Takeda Pharmaceutical Company Limited Tricyclic compound

Also Published As

Publication number Publication date
EA200970849A1 (ru) 2010-04-30
EP2134714A1 (en) 2009-12-23
BRPI0808791A2 (pt) 2017-05-02
NZ579360A (en) 2011-06-30
US20080293694A1 (en) 2008-11-27
US8138333B2 (en) 2012-03-20
EA016592B1 (ru) 2012-06-29
CA2679346A1 (en) 2008-09-18
AU2008225753A1 (en) 2008-09-18
WO2008110598A1 (en) 2008-09-18
CN101631787A (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
AU2007271188B2 (en) Indoles as 5-HT6 modulators
CN103664973B (zh) 螺羟吲哚化合物及其作为治疗剂的用途
CA2540861A1 (en) Novel tetraydrospiro{piperidine-2,7' -pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-ht6 receptor -related disorders
US8138333B2 (en) Sulfonyl-indole derivatives
BRPI0720131A2 (pt) Glicocorticoides miméticos, métodos para fazê-los, composições farmacêuticas e usos dos mesmos.
AU2009263037A1 (en) Alkynyl alcohols as kinase inhibitors
CZ20031707A3 (cs) Substituované pyrrodochinoliny a pyridochinoliny jako agonisté a antagonisté serotoninu
US7960374B2 (en) Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders
JP2009507037A (ja) 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン
WO2006062481A1 (en) New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
HK1134819A (en) Tricyclic isoquinoline derivatives for treatment of obesity
NZ577103A (en) 8-Sulfonyl-1,3,4,8-tetrahydro-2H-[1,4]oxazepino[6,7-e]indole derivatives and their use as 5-HT6 receptor ligands
KR20070020373A (ko) 5-HT6 수용체-관련 장애의 치료에 유용한 신규한 테트라히드로스피로{피페리딘-2,7'-피롤로[3,2-b]피리딘} 유도체 및 신규한 인돌 유도체

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110314

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120517